Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Tetrabenazine

Nature Reviews Drug Discovery volume 8, pages 17–18 (2009)Cite this article

Abstract

In August 2008, tetrabenazine (Xenazine; Ovation Pharmaceuticals/Biovail) was approved by the US FDA for the treatment of chorea associated with Huntington's disease. This makes it the first treatment to be approved in the US for a symptom of this neurodegenerative disorder.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Tetrabenazine.

References

  1. Leavitt, B. R. & Hayden, M. R. in Kelley's Textbook of Internal Medicine. 4th ed. (Lippincott, Williams and Wilkins, Philadelphia, 2000).

    Google Scholar 

  2. Landles, C. & Bates, G. P. Huntingtin and the molecular pathogenesis of Huntington's disease. EMBO Rep. 5, 958–963 (2004).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Graham, R. K. et al. Cleavage at the caspase 6 site in huntingtin is required for motor dysfunction, neurodegeneration and excitotoxicity in Huntington Disease. Cell 125, 1179–1191 (2006).

    Article  CAS  PubMed  Google Scholar 

  4. Grimbergen, Y. A. & Roos, R. A. Therapeutic options for Huntington's disease. Curr. Opin. Invest. Drugs 4, 51–54 (2003).

    CAS  Google Scholar 

  5. Quinn, G. P., Shore, P. A. & Brodie, B. B. Biochemical and pharmacological studies of RO1-9569 (tetrabenazine), a non-indole tranquilizing agent with reserpine-like effects. J. Pharmacol. Exp. Ther. 127, 103–109 (1959).

    CAS  PubMed  Google Scholar 

  6. Dalby, M. A. Effect of tetrabenazine on extrapyramidal movement disorders. BMJ 2, 422–423 (1969).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Jankovic, J. Tetrabenazine in the treatment of hyperkinetic movement disorders. Adv. Neurol. 37, 227–289 (1983).

    Google Scholar 

  8. Ondo, W. G. et al. Tetrabenazine treatment for Huntington's disease associated chorea. Clin. Neuropharmacol. 25, 300–302 (2002).

    Article  CAS  PubMed  Google Scholar 

  9. Zheng, G., Dwoskin, L. P. & Crooks, P. A. Vesicular monoamine transporter 2: role as a novel target for drug development. AAPS J. 8, E682–E692 (2006).

    Article  PubMed  PubMed Central  Google Scholar 

  10. Food and Drug Administration. FDA labelling information. FDA web site [online], (2008).

  11. Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 66, 366–372 (2006).

  12. Frank, S. et al. Functional decline due to chorea in Huntington's disease. Neurology 62, A204 (2004).

    Article  Google Scholar 

  13. National Institute of Neurological Disorders and Stroke (NINDS). Huntington's disease: hope through research. NINDS web site [online], (2008).

  14. IMS MIDAS (2007).

  15. Gibbs, L. NewCrest Biovail Research Report (New Crest, 8 Oct 2008).

Download references

Author information

Authors and Affiliations

  1. Blair R. Leavitt and Michael R. Hayden are at the Centre for Molecular Medicine and Therapeutics, Child and Family Research Institute, University of British Columbia, 950 West 28th Avenue, Vancouver, British Columbia V5Z 4H4, Canada.,

    Michael R. Hayden & Blair R. Leavitt

  2. Uma Yasothan is at IMS Health, 7 Harewood Avenue, London NW1 6JB, UK.,

    Uma Yasothan

  3. Peter Kirkpatrick is at Nature Reviews Drug Discovery. mrh@cmmt.ubc.ca; UYasothan@de.imshealth.com; p.kirkpatrick@nature.com,

    Peter Kirkpatrick

  4. UYasothan@de.imshealth.com,

    Peter Kirkpatrick

Authors
  1. Michael R. Hayden
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Blair R. Leavitt
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Uma Yasothan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hayden, M., Leavitt, B., Yasothan, U. et al. Tetrabenazine. Nat Rev Drug Discov 8, 17–18 (2009). https://doi.org/10.1038/nrd2784

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd2784

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing